Camidanlumab tesirine CD25 HL Hodgkin lymphoma refractory ADC

Indicated For

relapsed or refractory classic Hodgkin lymphoma

About This Medication

# Camidanlumab Tesirine Patient Guide: How to Get Camidanlumab Tesirine at Low or No Cost **Important Notice: Camidanlumab tesirine (also known as Cami or ADCT-301) is currently an investigational drug and not FDA-approved.** As of the latest available information, ADC Therapeutics has paused its Biologics License Application (BLA) for relapsed or refractory Hodgkin lymphoma due to FDA requirements for additional confirmatory trials[5][6]. There is **no commercial patient assistance program** available because the drug is not yet approved for widespread use. This guide provides information on the drug, clinical trial access options, and general resources for financial support if/when it becomes available. Always consult your healthcare provider for personalized advice. ## About Camidanlumab Tesirine Camidanlumab tesirine is an **antibody-drug conjugate (ADC)** designed to target CD25, a protein often found on cancer cells in certain lymphomas. It delivers a potent chemotherapy agent directly to cancer cells, minimizing damage to healthy tissues[1][3][7]. **Primary Use in Trials:** It's being studied for **relapsed or refractory classical Hodgkin lymphoma (R/R cHL)**—a type of blood cancer that returns or doesn't respond to standard treatments like brentuximab vedotin (Adcetris) and PD-1 inhibitors (e.g., nivolumab or pembrolizumab)[2][4][6][7]. Phase 2 trial results showed promising outcomes: an **overall response rate (ORR) of 70%**, with **33% achieving complete response (CR)** in heavily pretreated patients. Median duration of response was 13.7 months, and progression-free survival was 9.1 months[3][4][5][7]. **How It's Given:** Intravenous (IV) infusion every 3 weeks, starting at 45 μg/kg for the first two cycles, then 30 μg/kg for up to 1 year (or longer case-by-case if benefiting). Patients receive premedication with dexamethasone to reduce side effects[3][7]. **Common Side Effects:** Fatigue, nausea, anemia, infections, and infusion-related reactions. Serious risks include low blood counts, liver issues, and edema. In trials, 27% discontinued due to adverse events[3][7]. Since it's experimental, access is limited to **clinical trials**. Search ClinicalTrials.gov (NCT02432235 or ADCT-301 studies) for open sites[2]. ## Who Qualifies for Access? No commercial program exists, so eligibility focuses on **clinical trial criteria**: - Adults (typically 18+) with confirmed R/R cHL. - Failed ≥3 prior therapies (or ≥2 if transplant-ineligible), including brentuximab vedotin and checkpoint inhibitors[6][7]. - Good performance status (able to carry out daily activities). **Financial Need:** Trials often cover drug costs, but travel/ lodging may not. Programs like CancerCare or Leukemia & Lymphoma Society can help with co-pays or support. ## Income Eligibility Breakdown **No specific patient assistance program income thresholds apply** because camidanlumab tesirine lacks a commercial program. For reference, typical U.S. pharma assistance programs use **400-500% of the Federal Poverty Level (FPL)**. Here's a general FPL table (2026 estimates; check HHS.gov for exacts): | Household Size | 400% FPL (Annual Income) | 500% FPL (Annual Income) | |---------------|---------------------------|---------------------------| | 1 (Individual) | ~$60,000 | ~$75,000 | | 2 (Couple) | ~$81,000 | ~$101,000 | | 3 | ~$102,000 | ~$127,000 | | 4 | ~$123,000 | ~$154,000 | *Notes: Add ~$21,000 per additional person for 400% FPL. Programs may exclude high assets or certain income types.* ## Insurance Requirements **Not applicable for commercial use yet.** In trials: - Medicare/Medicaid patients may qualify if trial covers drug. - Private insurance often required for non-trial care, but investigational drugs aren't covered. - Trial sponsors (ADC Therapeutics) typically handle costs[5]. ## Step-by-Step Application Process for Trial Access 1. **Discuss with Your Doctor:** Ask your oncologist if you meet R/R cHL trial criteria. They can check eligibility[2][6]. 2. **Search Trials:** Use ClinicalTrials.gov, search "camidanlumab tesirine" or NCT02432235. Contact listed coordinators[2]. 3. **Contact Manufacturer:** Reach ADC Therapeutics medical info (via their site or 1-800 numbers if available) for trial sites[1][8]. 4. **Submit Screening:** Provide medical records, biopsy proof, prior treatment history. Expect tests (scans, bloodwork)[7]. 5. **Enroll if Eligible:** Sign consent; trial provides drug free. 6. **Financial Aid:** Apply to NeedyMeds.org, PAN Foundation, or LLS for ancillary costs. ## Timeline and Delivery **Trial Enrollment:** 2-4 weeks from screening to first dose, depending on site availability. **Treatment:** Every 3 weeks IV at clinic/hospital. **Duration:** Up to 1 year; extensions possible[3][7]. **No home delivery**—administered in medical settings. ## Alternatives if Denied Trial Access - **Other Trials:** PD-1 inhibitors, CAR-T (e.g., brentuximab combos). - **Approved Drugs:** Brentuximab vedotin, nivolumab, pembrolizumab for R/R cHL. - **Compassionate Use:** Ask ADC Therapeutics for expanded access (rare pre-approval)[5]. - **Support Orgs:** Leukemia & Lymphoma Society (1-800-955-4572) for co-pay help. ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Camidanlumab tesirine status may change—verify with FDA, ADC Therapeutics, or your doctor. Trial risks include side effects; benefits not guaranteed. Income/FPL estimates approximate; consult official sources. Last updated based on data through 2025[5][7]. (Word count: 942)

Program information last verified: March 30, 2026